|Bid||115.00 x 900|
|Ask||115.20 x 800|
|Day's range||113.79 - 115.12|
|52-week range||61.61 - 115.40|
|Beta (5Y monthly)||0.83|
|PE ratio (TTM)||60.67|
|Forward dividend & yield||1.80 (1.57%)|
|Ex-dividend date||14 Jan 2021|
|1y target est||N/A|
As a major pharma company, AbbVie (NYSE: ABBV) delivers for its investors by developing and commercializing new drugs, like its best-selling arthritis treatment Humira. There's two reasons AbbVie is worth holding forever: its skill with drug development, and its generous dividend. Like many other pharma companies, AbbVie maximizes the revenue that it gets from each of its drug development projects by investigating their usefulness for multiple illnesses.
Within EPD, Abbott (ABT) is expected to have witnessed visible signs of rebound through Q4.
The Zacks Analyst Blog Highlights: Quest Diagnostics, Abbott, Becton, Dickinson and Co, Quidel and Hologic